文献速递临床试验与 GCP

临床试验启动阶段的精简与周期时间缩短

Streamlining and cycle time reduction of the startup phase of clinical trials.
PubMed 文献 · Trials · 2020-01-29

该研究在沙特阿拉伯利雅得King Fahad Medical City临床研究部开展,分析2016–2017年间13项申办方发起的临床试验中的8项,采用FOCUS-PDCA循环和鱼骨图分析识别启动阶段延迟因素,并实施干预方案。结果显示,干预后整个临床试验生命周期缩短了45.6%(干预前均值24.8周,SD 8.2周;干预后均值13.5周,SD 11.6周),主要延迟因素为缺乏明确的方案审批时间线和IRB会议不一致。

要点

  • 鱼骨图分析识别出两个主要延迟因素:缺乏明确的方案审批时间线和IRB会议不一致。
  • 实施干预方案后,临床试验整体生命周期缩短45.6%。
  • FOCUS-PDCA循环可用于优化临床试验启动流程。

核心结论

  • 多种因素导致临床试验启动阶段延迟,理解各因素的影响有助于优化和加速启动阶段执行。

研究设计与样本

  • 研究纳入2016至2017年间在沙特阿拉伯利雅得King Fahad Medical City临床研究部开展的13项申办方发起的临床试验,其中8项被分析以识别启动阶段指标数据。
  • 采用FOCUS-PDCA循环(查找改进区域-组织团队-澄清当前实践-理解变异/问题来源-选择策略-计划-执行-检查-处理)和鱼骨图分析。
  • 六项指标包括:首次联系中心至签署保密协议的时间、收到申办方问卷至完成的时间、审查方案和批准研究药物服务表单的时间、研究方案并批准药房和病理及临床检验医学表单的时间、收到IRB提交包至最终IRB批准的时间。
  • 计算干预方案实施前后各指标的平均(SD)时间,分析并比较临床试验平均周期时间的百分比降低,P值显著性水平设为P<0.05。

主要发现

  • 鱼骨图分析识别出的两个主要延迟因素为缺乏明确的方案审批和审查时间线以及IRB会议不一致。
  • 引入新干预方案后,整个临床试验生命周期缩短了45.6%(干预前均值24.8周,SD 8.2周;干预后均值13.5周,SD 11.6周)。

临床怎么用

  • 通过理解启动阶段各延迟因素的影响,可优化并加速临床试验启动阶段的执行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The startup phase of a clinical trial (CT) plays a vital role in the execution of new drug development. Hence, the aim of this study is to identify the factors responsible for delaying the CT startup phase. Further, it focuses on streamlining and reducing the cycle time of the startup phase of newly sponsored CTs. METHODS: Thirteen sponsored CTs conducted between 2016 and 2017 at the Clinical Research Department of King Fahad Medical City, Riyadh, Saudi Arabia, were considered for this study. Eight trials were analyzed to identify the data specific to startup metrics using the FOCUS-PDCA cycle (Find an improvement area-Organize a team-Clarify current practices-Understand the source of variation/problem-Select a Strategy-Plan-Do-Check-Act). Six measures incorporated in the metrics were (1) date of initial contact with site to the signing of confidentiality agreement, (2) date of receiving questionnaire from sponsor to date of its completion, (4) time taken to review protocol and approve investigational drug service form, and (5) time taken to study protocol and approve pharmacy and pathology and clinical laboratory medicine form and date of receipt of institutional review board (IRB) submission package to final IRB approval. Fishbone analysis was used to understand the potential causes of process variation. Mean (SD) time was calculated for each metric before and after implementation of the intervention protocol to analyze and compare percentage reduction in the mean cycle time of CTs. Data were represented as mean (SD), and the P value was calculated for each metric. The significance level was set at P < 0.05. RESULTS: Of the various potential factors of delay identified through fishbone analysis, the two major ones were lack of a well-defined timeline for approval and review of the study protocol and inconsistent IRB meetings. After introduction of the new intervention protocol, the entire CT life cycle was reduced by 45.6% (mean [SD], 24.8 [8.2] weeks vs. 13.5 [11.6] weeks before and after the intervention, respectively). CONCLUSION: Various factors are responsible for the delay of the startup phase of CTs, and understanding the impact of each element allows for optimization and faster execution of the startup phase of CTs.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Abu-Shaheen A, Al Badr A, Al Fayyad I, et al. Streamlining and cycle time reduction of the startup phase of clinical trials. Trials. 2020. PMID: 31996249. doi:10.1186/s13063-020-4079-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。